Thymalin
ImmuneTimalin — Synthetic Peptide
Overview
Thymalin (Russian brand: Timalin) is a heterogeneous polypeptide extract from calf thymus gland, containing a complex mixture of peptides with molecular weights between 1,000 and 10,000 Da. It is an approved pharmaceutical in Russia for immune deficiency states. Its active fractions have been identified and synthesized as distinct short peptides: Crystagen (EDP tripeptide), Vilon (KE dipeptide), and Thymogen (EW dipeptide) — all studied individually by Khavinson's group.
Thymalin occupies an unusual position in the peptide research landscape: it has human observational data from a 6–8 year study of 266 elderly patients that is exceptional in scope for this class of compound, while simultaneously lacking the randomized controlled trial design that Western regulatory bodies require. It is not approved by the FDA or EMA. In Western research peptide markets, Thymalin is sold as a lyophilized powder with limited standardization.
Molecular weight and formula fields are not applicable — Thymalin is a complex polypeptide mixture, not a single defined compound.
Mechanism of Action
Thymalin's mechanism reflects its heterogeneous composition:
**Immune restoration:** Component peptides (Crystagen/EDP, Vilon/KE) interact with DNA regulatory regions and histone proteins, upregulating immune gene expression including HSP gene HSPA1A, normalizing IL-6 secretion, and restoring CD3+/CD4+ T-cell counts and CD4+/CD8+ ratios in immunosenescent individuals. Phagocytic activity and NK cell function are also reported to increase in treated elderly subjects.
**Anti-aging epigenetic mechanism:** The active dipeptide and tripeptide fractions (KE, EW, EDP) are proposed to activate facultative heterochromatin in aged lymphocytes, restoring expression of genes silenced by age-related chromatin condensation — a mechanism consistent across multiple Khavinson-class peptides and observed in vitro in human aged lymphocytes.
**Thymic gland restoration:** Thymalin may partially restore age-related thymic involution by supporting thymocyte proliferation and cortex-medulla architectural integrity, as demonstrated in irradiated thymus animal models.
Research Dosing
Standard Russian clinical protocol (Timalin). Annual or biannual 10-day courses were used in the 6-year longevity study. Regulatory status: approved drug in Russia (Timalin); not approved by FDA or EMA. Not available as a standardized pharmaceutical in Western markets — sold as research compound.
Research data only. These dosing ranges are derived from published studies, primarily in animal models. This is not medical advice. No peptide discussed on this site is approved for human therapeutic use unless otherwise noted.
Published Studies
Peptides of pineal gland and thymus prolong human life
Khavinson VKh, Morozov VG — Neuroendocrinology Letters, 2003
Landmark 6–8 year observational study of 266 elderly patients (65–85 years) receiving annual Thymalin and/or Epithalamin courses vs. controls. Thymalin monotherapy reduced all-cause mortality approximately 2-fold over 6 years; combined Thymalin + Epithalamin reduced mortality 2.5-fold; 6-year continuous treatment reduced mortality 4.1-fold. This is the most frequently cited long-term human evidence for the Khavinson bioregulator class.
PMID: 14523363 →HumanLong-term effects of thymalin in reducing morbidity and mortality in the elderly
Korkushko OV, Khavinson VKh, Butenko GM, Shatilo VB — Journal of Anti-Aging Medicine, 2002
Related analysis from the same elderly cohort reporting a 2.0–2.4-fold reduction in respiratory disease incidence and improved immune parameters (CD3+, CD4+ T-cell counts, NK cell activity) over 6–8 years of Thymalin treatment, consistent with immune restoration as the primary mechanism.
PMID: 12577695 →